“…With the exception of two studies which included a small number of participants with a primary diagnosis of bipolar II or bipolar I disorder ( n = 3) ( Dubin et al, 2016 , Godfrey et al, 2021 ), participants had a primary diagnosis of current MDD using standard Diagnostic and Statistical Manual of Mental Disorders (DSM) DSM-IV, DSM-IV-TR or DSM 5 criteria ( American Psychiatric Association, 2013 , American Psychiatric Association, 2000 ). Some level of pharmacoresistance characterized the participants in nine studies; one study did not specify participants’ past treatment history or pharmacoresistance ( Zavorotnyy et al, 2020 ), and two did not require treatment resistance ( Luborzewski et al, 2007 , Erbay et al, 2019 ). Information on psychiatric comorbidities was available in five studies and included secondary diagnoses of attention deficit hyperactivity disorder, obsessive compulsive disorder, generalized anxiety disorder, social phobia, and post-traumatic stress disorder ( Croarkin et al, 2016 , Yang et al, 2014 , Dubin et al, 2016 , Erbay et al, 2019 , Godfrey et al, 2021 ).…”